Genomics Daily 🧬🤖Sep 25
🧬 CRISPR breakthrough: Supercharging CAR T cells by knocking out RHOG & FAS! 🚀 Precision immunotherapy just leveled up. 🔬 #CARTcells #CancerResearch #Genomics https://emmecola.github.io/genomics-daily
Genomics Daily

My GitHub page

Moreno Colaiacovo
Broermann AwardSep 18

Congratulations to Prof. Dr. Carl June & Prof. Dr. Michel Sadelain on receiving the 2025 Broermann Medical Innovation Award for the development of the CAR-T cell immunotherapy!

Their work stands as a shining example of how research excellence can translate into real-world impact!

#cancer #cartcells #research

LaborjournalApr 17
In München und Singapur werkelt das #Startup Eximmium an neuen Antikörpern gegen #Krebs – und macht sich dabei ein ungeklärtes Phänomen von Krebszellen zunutze. @InsertCaffeine erklärt uns das Ganze genauer: https://www.laborjournal.de/editorials/3231.php #Biotech #CarTCells #Antikörper
Eximmium nutzt extrazelluläre Vesikel für die Herstellung von Anti-Krebs-Antikörpern

Das Mnchner Startup Eximmium nutzt extrazellulre Vesikel von Tumorzellen um in diesen neue Antikrper zur Behandlung von Krebs herzustellen

Laborjournal
Thiago CarvalhoJul 17, 2024
'A year ago, Caribou Biotherapeutics’ CEO was telling Fierce Biotech that the company’s natural killer (NK) cell therapy program was the “tip of the spear” for its solid tumor strategy and there were no plans to pause this work to conserve cash.
Now, with the biotech eyeing up ways to keep the money flowing into 2026, the CRISPR-focused company has decided that the preclinical CAR-NK research needs to go—along with 12% of Caribou’s workforce'
#Immunotherapy #Immunology #CARTcells
https://www.fiercebiotech.com/biotech/caribou-cuts-nk-cell-therapy-program-lays-12-staff-fund-car-t-priorities
Caribou cuts NK cell therapy program, lays off 12% of staff to fund CAR-T priorities

A year ago, Caribou Biotherapeutics’ CEO was telling Fierce Biotech that the company’s natural killer (NK) cell therapy program was the “tip of the spear” for its solid tumor strategy and there wer | Eyeing up ways to keep the money flowing into 2026, the CRISPR-focused company has decided that the preclinical CAR-NK research needs to go—along with 12% of Caribou’s workforce.

Fierce Biotech
Thiago CarvalhoJul 14, 2024

'Twenty-nine different Car-T treatments for autoimmune diseases, ranging from the muscle inflammation condition myositis to multiple sclerosis, are now being tested in clinical trials by drugmakers including Novartis and Bristol Myers Squibb'

#Immunology #Autoimmunity #CARTcells

https://www.ft.com/content/a974f4c1-bb8a-4a1b-9d88-a2cf14be5c6e

Cell therapy offers ‘single shot’ hope to autoimmune disease patients

Use of Car-T for lupus could drive surge in demand for a treatment that was first approved for blood cancers

Thiago CarvalhoJul 12, 2024
'These studies have helped to answer “some of the questions that were precipitated by the FDA announcement,” Maus said. They still have not found definitive evidence that CAR-T therapy has directly caused new cancers, she said, and scientists continue to suspect that such an event would be extremely rare.'
#Immunology #Immunotherapy #CARTcells
https://www.statnews.com/2024/07/12/cancer-car-t-therapy-fda-secondary-cancers/?utm_campaign=rss
CAR-T cell therapy’s complications, as well as its benefits, become clearer in ‘flurry’ of cancer studies

After the FDA expressed concern about CAR-T cancer treatment, a flurry of studies has yielded more information about complications but no definite link to secondary cancers.

STAT
Thiago CarvalhoJul 6, 2024
'Even without exposure to antigens, some CARs increase proliferation and nutrient uptake in T cells. Using stable isotope tracers and mass spectrometry, we observed basal metabolic fluxes through glycolysis doubling and amino acid uptake overtaking anaplerosis in CAR-T cells harbouring a rituximab scFv, unlike other similar anti-CD20 scFvs.'
#Immunology #Immunotherapy #CARTcells
https://www.nature.com/articles/s42255-024-01034-7
Extracellular domains of CARs reprogramme T cell metabolism without antigen stimulation - Nature Metabolism

Lakhani et al. offer insight into the metabolic reconfigurations driven in T cells by chimeric antigen receptors (CARs) that differ only in their extracellular domains.

Nature
Thiago CarvalhoMay 31, 2024
'However, the established use of viral vectors for genetic engineering of CAR immune cells is still subject to particular safety concerns and requires further improvements. 1 Consequently, non-viral methods for immune cell engineering are gaining increasing interest. In this context, transposon-based technologies represent a promising alternative engineering technology that enables safe genomic insertions of large cargo, such as multi-cistronic CAR-expression cassettes, using fast and cost-effective manufacturing processes '
#Immunology #Immunotherapy #CARTcells
https://www.cell.com/molecular-therapy-family/molecular-therapy/abstract/S1525-0016(24)00325-3?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1525001624003253%3Fshowall%3Dtrue
Arjan BoltjesMay 21, 2024

" The insights derived from this analysis do not only support a CD19 CAR T cell-mediated reset of the memory B cell compartment, but also the parallel inhibition of the interferon signature
in #monocytes and #Tcells of #SLE patients"

https://insight.jci.org/articles/view/179433

Striking that this apparently works better in getting rid of certain memory #Bcells than anti-CD20 antibodies.

#scRNAseq #TCR #carTcells #OpenAccess #science

JCI Insight - Selective CAR-T cell mediated B cell depletion suppresses interferon signature in SLE

Thiago CarvalhoMay 20, 2024
'Although T cell depletion was greatly enhanced by CD47 blockade in our studies, our data demonstrate that macrophage phagocytosis limits the persistence of adoptively transferred T cells even in the absence of CD47–SIRPα blockade'
#Immunotherapy #Immunology #CARTcells
https://www.nature.com/articles/s41586-024-07443-8#Sec10
Engineered CD47 protects T cells for enhanced antitumour immunity - Nature

Combination of TCR or CAR T cells expressing the engineered CD47 variant 47E with anti-CD47 antibody therapy results in synergistic antitumour efficacy due to T cell resistance to clearance by macrophages, while maintaining macrophage recruitment into the tumour microenvironment.

Nature